K562/GM-CSF Vaccination in Combination with Imatinib Mesylate as Booster for Chronic Myeloid Leukemia Patients Previously Vaccinated on Protocol J0345
B Douglas Smith
1.Determine whether a series of four K562/GM-CSF vaccinations (+/- imiquimod cream) can serve as an immunologic ?booster? and result in molecular remissions in subjects considered non-responders to imatinib mesylate + a primary series of K562/GM-CSF vaccines OR return subjects who have recurrent measurable disease after an initial complete molecular remission to imatinib mesylate + and a series of K562/GM-CSF vaccines to molecular negativity.
Patients with AML who completed the entire protocol of J0345 and still ahve evidence of disease.
4 vaccines seperated by 3 weeks. Each vaccine will be given over 10 seperate injectiopn sites to the lower legs and upper arm.
09/18/2014 04:03 AM